Latest

Seaport Therapeutics reports Q2 2026 results, cites GlyphAgo Phase 1 win and IPO close

The company said cash of $427.3 million should fund operations into 2029 as it advances GlyphAllo and GlyphAgo through mid-stage trials.

SEC filing